BrainChip (ASX:BRN) Opens Sequora Edge AI Processor IP to Licensing After Receiving AKD1500 Chip Volumes

Aditi Sarkar

02 November 2026 10:36 PM AEDT

BrainChip (ASX:BRN) Opens Sequora Edge AI Processor IP to Licensing After Receiving AKD1500 Chip Volumes

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

BrainChip made its Sequora edge AI processor IP commercially available on 14 October 2026 for chip developers.
About 20,000 AKD1500 chips arrived in September 2026, with remaining units expected by the end of November.
Customer receipts reached US$273,000 in the Sep-2026 quarter, while net operating cash outflow fell 9% to US$4.3 million.
Cash stood at US$16.4 million at 30 September 2026, equal to roughly four quarters of funding.

BrainChip Holdings Ltd (ASX:BRN) has added a second product line to its Akida neuromorphic platform, making the Sequora edge AI processor IP commercially available on 14 October 2026, weeks after taking delivery of its first Volume shipment of AKD1500 chips.

The company develops low-power AI processors and licenses the underlying intellectual property to semiconductor and system developers, while also selling chips and development boards.

Sequora Brings Generative AI to the Device

Sequora is designed to run generative AI and large language models of up to about 3 billion parameters on the device rather than in the cloud, retaining Akida's low-power, local processing. The company also added run-time branching, which it says supports certification for automotive, medical and avionics uses.

Targeted markets include industrial, automotive, aerospace and defence, consumer and medical applications. Chief Executive Sean Hehir said the release was delivered on the timetable set out in the May 2026 roadmap. Customer engagement has begun, but the company has not forecast licensing Revenue and has said it cannot yet provide reliable projections.

AKD1500 Chips Move Into Customer Hands

About 20,000 AKD1500 chips were received in September 2026, following roughly 2,000 in June, with the balance expected by the end of November. Commercial M.2 board sales started in July and the AKD1500 PCIe development board became available in September.

Defence contractor Parsons has received its full initial order of 10,000 chips and started Manufacturing a custom M.2 board. Neuromorphyx received 1,200 chips for board production, and Onsor Technologies has a 2,000-chip order for EEG glasses that awaits Omani health ministry approval.

Receipts Remain Modest as Spending Eases

Customer receipts for the Sep-2026 quarter were US$273,000, mainly from chip and board sales, bringing the year-to-date total to US$1.09 million. Net operating cash outflow fell 9% to US$4.3 million, with Research and Development payments of US$2.1 million the largest single item.

Cash declined to US$16.4 million at 30 September 2026 from US$20.3 million at the end of June, which the company estimates covers about four quarters of operations. In August, it received net proceeds of A$688,582 from the sale of Collateral shares held by LDA Capital before its Put Option agreement expired.

Tape-Outs and Royalty Timeline Shape the Path Ahead

The AKD2500 tape-out remains on track for December 2026, with first engineering samples expected in early Q3 2027, subject to foundry capacity. Korean licensee EdgeAI is targeting a multi-project wafer tape-out in December 2026, while Frontgrade Gaisler expects commercial production of its GR801 chip in 2027. Management has indicated royalty revenue could potentially begin in late 2027, depending on customer production schedules.

Shares were priced at A$0.11 on 2 November 2026, up 4.76% on the day, giving a Market Capitalisation of A$250.35 million. The stock was down 45% over 12 months.

FAQs

Q: What is BrainChip's Sequora?

A: Sequora is an edge AI processor IP core that runs generative AI and language models of up to about 3 billion parameters on the device, available for licensing from 14 October 2026.

Q: How much cash did BrainChip hold at 30 September 2026?

A: BrainChip held US$16.4 million, which it estimates is about four quarters of funding.

Q: When does BrainChip expect royalty revenue?

A: Management has indicated royalty revenue could potentially begin in late 2027, depending on customer production schedules.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.